Introduction
The structure and biochemical functions of cardiac mitochondria are altered during ischaemia-reperfusion (IR).
1,2 Impaired mitochondrial function after ischaemia are disastrous for the heart and are manifested as depressed respiratory chain complex activity, 3 decreased NADH dehydrogenase activity, 4 lower mitochondrial membrane potential (DCm), 5 loss of adenosine triphosphate (ATP) synthesis, increased ATP hydrolysis, 6 and Ca 2+ overload-induced mitochondrial permeability transition pore (mPTP) opening. 7 Mitochondrial oxidative stress has been also reported to suppress tricarboxylic acid cycle (TCA) enzymes, modify mitochondrial proteins, 5, 8 trigger mPTP opening, 9 induce mitochondrial malfunction, 10 and promote the release of pro-apoptotic proteins, 11 and subsequently leading to cell death via apoptosis or necrosis. 12 In this context, mitochondria are a major target of IR injury. 6 Thus, the preservation of mitochondrial function is essential to limit myocardial damage in ischaemic heart disease. Among the possible mechanisms of cardioprotection, ischaemic post-conditioning (IPost) is one of the most effective mechanisms for protecting mitochondrial function against IR damage. IPost during the early reperfusion period prevents the opening of mPTPs by changing the pH. 13, 14 IPost also attenuates mitochondrial Ca 2+ accumulation 15 and mitochondrial reactive oxygen species (ROS) generation during reoxygenation. 16 Additionally, the activation of the mitochondrial ATP-sensitive potassium channel in IPost is thought to play a protective role in limiting reperfusion injury. 17 Pharmacological approaches to studying mitochondrial regulation have been focused either clinically or experimentally. Recently, we have developed NecroX compounds, which are cell permeable necrosis inhibitors with antioxidant activity that localize mostly in the mitochondria. 18 NecroX-5 is one of the derivatives of NecroX series compounds, whose chemical composition is C 25 H 31 N 3 O 3 S . 2CH 4 O 3 S with molecular weight 453.61 (see Supplementary material online, Figure S1A ). We found that the cytoprotective effect of NecroX-5 could be due to the mitochondrial ROS scavenging activity. 18 NecroX-5 effectively inhibited the generation of oxidized low-density lipoprotein cholesterol, tertiary-butyl hydroperoxide-induced † These authors contributed equally to this work.
mitochondrial ROS generation, doxorubicin-induced cell death in different cell lines, and CCl 4 -induced hepatotoxicity in a rat model. 18 NecroX-7, another derivative that is functionally and chemically very similar to NecroX-5, reduced hepatic necrosis to IR injury compared with that in the control group. 19 Although the cellular protective effect of NecroX-5 on various in vitro and in vivo models was demonstrated, the mode of action of this compound on the cellular or mitochondrial protective mechanism is still unclear. Therefore, the aim of this study was to validate the effect of NecroX-5 in preventing myocardial infarction (MI) in rats with ischaemic heart disease and to provide support for the use of NecroX-5 as a medication against MI. Thus, we examined the protective effects and the mechanism of action of NecroX-5 on rat heart mitochondria in a hypoxia/reoxygenation (HR) model. We demonstrated that NecroX-5 post-hypoxic treatment improved mitochondrial function in the HR model and suppressed mitochondrial calcium overload. Additionally, we further investigated the possible mechanism of how NecroX-5 inhibits mitochondrial Ca 2+ overload in HR. NecroX-5 showed a strong inhibitory effect on the mitochondrial Ca 2+ uniporter (MCU) and this novel effect of NecroX-5 may result in preserving mitochondrial function and limiting infarct size in HR.
Methods
The details of each experiment are available in the Supplementary material online. 
Ethics statement

Isolation of hearts and cardiac myocytes
Eight-week-old male Sprague -Dawley rats (weight, 200 -250 g each) were deeply anaesthetized with sodium pentobarbital (100 mg/kg intraperitoneally). 20 The adequacy of anaesthesia was monitored by heart rate, muscle relaxation, and the loss of sensory reflex response, i.e. nonresponse to tail pinching. Each heart was mounted and perfused with normal Tyrode's (NT) solution equilibrated with 95% O 2 and 5% CO 2 at 378C for 10 min in the Langendorff system to remove all blood. Individual hearts were used for testing infarction size, performing experimental protocols, and isolating myocytes and mitochondria. Single cardiac myocytes were isolated using an enzymatic dissociation method as described previously 21 (see Supplementary material online, Methods).
NecroX-5 concentration and fluorescence
The optimal dose (10 mM) of NecroX-5 was determined in our previous study (see Supplementary material online, Figure S1B and Table S1 ).
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Before applying fluorescence-based analysis, we tested the fluorescence of NecroX-5 at the various wavelengths (510/580, 488/525, 488/535, and 550/590 nm) using fluorescence reader, SpectraMax M2 (Molecular Device, USA). The fluorescence intensities of NecroX-5 (10 mM) at all wavelengths were not significantly different from NT solution (see Supplementary material online, Figure S2A ). In addition, NecroX-5 treatment itself did not altered cells' autofluorescence in the absence of the fluorescent dye (see Supplementary material online, Figure S2B and C). 
Cardiac and myocyte perfusion
Triphenyltetrazolium chloride staining
Infarct size was examined by using tissue triphenyltetrazolium chloride (TTC) staining as described in our previous study 22 (see Supplementary material online, Methods).
Isolation of mitochondria
Cardiac mitochondria isolation was performed using the differential centrifugation method as described previously 5, 22 (see Supplementary material online, Methods).
Measurement of ROS production
Cells were incubated at 378C with MitoSOX Red (5 mM; excitation/emission: 510/580 nm) to detect changes in mitochondrial O 2 2 levels. After washing twice with the Kraft-Brühe solution, myocytes were placed in a perfusion chamber at room temperature. The fluorescence intensity was measured every 20 s by using a confocal microscope with LSM-510 META software. Regions of interest in the myocytes were selected to represent changes in fluorescence intensity over time, and the background was identified as an area without cells. MitoSOX Red intensity 2 min after exposed to NT solution expressed as a percentage of the baseline value. The fluorescence intensity was analysed as a percentage of baselines after subtraction of autofluorescence in the absence of the fluorescent dye. ROS production in isolated mitochondria was also evaluated by flow cytometry as described previously 23 (see Supplementary material online, Methods).
Measurement of mitochondrial membrane potential
To measure DCm, myocytes were stained with 0.1 mM tetramethylrhodamine ethyl ester (TMRE; excitation/emission: 564/580 nm) for 30 min at room temperature. Next, they were washed and placed in a perfusion chamber. Fluorescence was detected every 30 s by laser scanning confocal microscopy. Images were analysed using LSM-510 META software as described in the section for the measurement of ROS production (Carl Zeiss, Jena, Germany). The DCm in isolated mitochondria was also evaluated by flow cytometry, as changes in TMRE fluorescence at 580 nm (FL2). The mean values were calculated using CellQuest (version 5.2).
Oxygen consumption
Mitochondrial oxygen consumption was measured in a 600 mL airsaturated chamber at room temperature, using a fibre-optic oxygen electrode (Instech). The respiration medium consisted of 145 mM KCl, 30 mM HEPES, 5 mM KH 2 PO 4 , 3 mM MgCl 2 , 0.1 mM EGTA, and 0.1% bovine serum albumin at pH 7.4. Mitochondrial state 4 was initiated with the addition of 5 mM glutamate/malate as a substrate. After steady state, state 3 respiration was stimulated by adding 0.5 mM adenosine diphosphate (ADP) to the medium. 8 Oxygen consumption is expressed as nmol
is the ratio of ADP-stimulated state 3 respiration to state 4 respiration.
NecroX-5 prevents hypoxia/reoxygenation injury
Measurement of mitochondrial calcium
Changes in mitochondrial calcium levels were detected with Rhod-2 AM (5 mM; excitation/emission: 533/576 nm). Cells were incubated with Rhod-2 AM using a cool -warm method 5 and washed twice with the Kraft-Brühe solution. The fluorescence intensity was measured using a confocal microscope as described above. We used an MCU inhibitor RuR to validate the effect of NecroX-5 on MCU. Ouabain and histamine were used to overload mitochondrial Ca 2+ as experimental controls.
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2.11 Whole-cell patch-clamp recording of L-type Ca 21 current
For recording L-type Ca 2+ current, myocytes were placed in a chamber mounted on an inverted microscope and continuously perfused with extracellular (bath) solution (143 mM NaCl, 5.4 mM KCl, 0.33 mM NaH 2 PO4, 1.8 mM CaCl 2 , 0.5 mM MgCl 2 , 5.0 mM HEPES, and 16.6 mM glucose, adjusted to pH 7.4 with NaOH). When filled with a standard internal solution consisting of 32 mM CsCl, 100 mM Cs-Asp, 10 mM EGTA, 10 mM HEPES, and 5 mM MgATP, adjusted to pH 7.25 with CsOH, and placed into the bath solution, the patch-pipette tip resistances were 2-3 MV. Whole-cell patch-clamp recordings were made using an Axon interface and Axonpatch 1C amplifier (Axon Instruments, Union City, CA, USA). Experimental parameters were controlled using PatchPro software. To allow equilibration of the pipette solution with the cytosol, the current recordings were started 4 min after the rupture of the membrane patch. Data were analysed using Origin 8.0 software (Microcal Software, Inc., Northampton, MA, USA).
Measurement of cardiac function
The hearts were perfused with the Krebs -Henseleit buffer containing (in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO 4 , 1.8 CaCl 2 , 24.8 NaHCO 3 , 1.2 KH 2 PO 4 , and 10 glucose, which was heated to 378C and gassed with 95% O 2 /5% CO 2 . A latex balloon connected to a pressure transducer was inserted into the left ventricle through the left atrium. The left ventricular pressure and heart rate were continuously recorded with a PowerLab system (AD Instruments, Mountain View, CA, USA). All hearts were then allowed to stabilize for at least 20 min. Hypoxia was induced with ischaemic solution for 15 min. Reoxygenation was initiated by switching to the Krebs -Henseleit buffer for 50 min. NecroX-5 (10 mM) was treated for 10 min at the start of and then further re-perfused with the Krebs -Henseleit buffer for 40 min. Coronary flow was measured before the hypoxic period and at the end of the reoxygenation period by collecting the effluent during 1 min. Cardiodynamic data, including heart rate, left ventricular end-diastolic pressure (LVEDP), left ventricular developing pressure (LVDP), and the maximum and minimum of the first derivative of left ventricular pressure (maximum +dP/dt and minimum 2dP/dt), were continuously recorded with the MLT0380/A pressure transducer (AD Instruments) and analysed using analysis software (LabChart pro 7.0 version 7.2.1).
Statistics
Data are presented as mean + standard error of the mean. The differences between the control and the treatment were evaluated by two-tailed one-way analysis of variance (ANOVA) and the control to treatment comparison over time was tested with a two-tailed two-way ANOVA. We used the Tukey post hoc comparison for the comparison of means using Origin software (version 7.0220, OriginLab. USA). The differences with a P-value of ≤0.05 were considered statistically significant.
Results
NecroX-5 post-hypoxic treatment limits cardiac infarct size in HR and improves cardiac function
The HR treatment induced a severe myocardial infarction (MI) (60.99 + 1.79% of total area) compared with that in the normal perfusion control (9.27 + 1.82%), whereas post-NecroX-5 treatment significantly attenuated HR-induced MI (17.38 + 2.72%; Figure 1A and B; see Supplementary material online, Figure S3 ). The cell viability of isolated myocytes treated with NecroX-5 was also markedly higher compared with that of the control (95.83 + 7.22 vs. 62.5 + 12.5%) ( Figure 1C ; see Supplementary material online, Figure S4 ). Treatment with NecroX-5 significantly recovered LVEDP and LVDP during the reoxygenation period (see Supplementary material online, Table S2 ).
NecroX-5 post-hypoxic treatment improves mitochondrial oxygen consumption
Mitochondrial oxygen consumption was examined in the HR group and the NecroX-5 post-hypoxic treatment group ( Figure 1D ). 
NecroX-5 decreases mitochondrial oxidative stress induced by reoxygenation
NecroX-5 markedly suppressed the overproduction of mitochondrial ROS during reoxygenation in both isolated cardiomyocytes (Figure 2A and B) and isolated mitochondria ( Figure 2C and D). Mitochondrial O 2 2 production increased in both groups during reoxygenation, but the increase was attenuated in the NecroX-5 group compared with the HR group (Figure 2A and B) . In the flow cytometry analysis, the intensities of MitoSOX Red and H 2 DCF-DA were significantly diminished by NecroX-5 post-treatment compared with HR as described in Figure 2C and D and Supplementary material online, Figure S5A and B.
3.4 NecroX-5 post-hypoxic treatment preserves DCm TMRE intensity was markedly attenuated in the NecroX-5-treated group compared with that in the HR group in both isolated cardiomyocytes ( Figure 2E and F ) and isolated mitochondria ( Figure 2G ), particularly with prolonged reoxygenation times. At the end of the experimental protocol, the TMRE intensities of the HR and NecroX-5 groups were depolarized to 11.10 + 7.12 and 64.86 + 3.47%, respectively, of the basal level (n ¼ 6). In the mitochondria, which were isolated after the reoxygenation period, DCm in the NecroX-5 group was 1.4-fold higher than that in the HR group ( Figure 2G ; see Supplementary material online, Figure S5C ). Figure 3D -F), indicating that inhibiting MCU after hypoxia is beneficial against HR injury. We further tested whether NecroX-5 has a direct effect on HR-independent mitochondrial calcium overload. Ouabain, an Na 2+ / K + ATPase inhibitor in the plasma membrane, was used to induce HR-independent mitochondrial Ca 2+ overload ( Figure 4A-C) .
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Treatment with ouabain alone induced maximal mitochondrial Ca 2+ overload; consequently, the myocytes were contracted (data not shown). Both NecroX-5 and RuR reduced the ouabain-induced mitochondrial Ca 2+ overload.
We also tested whether pre-treatment with NecroX-5 before the hypoxic or ouabain treatment could suppress mitochondrial Ca 2+ overload. Unlike post-treatment, pre-treatment with NecroX-5 did not inhibit the HR or ouabain-induced mitochondrial Ca 2+ overload (see Supplementary material online, Figure S6 ) and did not inhibit the collapse of DCm during reoxygenation (data not shown). To confirm our hypothesis that MCU is a molecular target of NecroX-5, we tested the MCU inhibitory effect of NecroX-5 in the presence of histamine, an activator of MCU. Histamine treatment induced a mitochondrial Ca 2+ peak, and NecroX-5 suppressed this effect of histamine on mitochondrial Ca 2+ uptake ( Figure 4D and E).
These results indicate that NecroX-5 can prevent HR-induced mitochondrial Ca 2+ overload by directly inhibiting MCU.
3.6 NecroX-5 has no effect on the L-type Ca 21 channel
We investigated whether Ca 2+ regulation by the L-type Ca 2+ channel was involved in the effect of NecroX-5 on mitochondrial Ca 2+ . The patch-clamp recordings of L-type Ca 2+ current in the presence and absence of NecroX-5 demonstrated that NecroX-5 had no effect on the L-type Ca 2+ channel activity ( Figure 5 ). NecroX-5 prevents hypoxia/reoxygenation injury
Discussion
The objective of the present study was to evaluate the cardioprotective effect of NecroX-5 against HR injury, elucidate the possible mechanism for limiting cardiac mitochondrial damage, and validate the use of this compound as a medication against ischaemic heart disease. During the first few minutes of reoxygenation, mitochondria encounter harsh environmental changes, with mitochondrial Ca 2+ overload and a burst of mitochondrial ROS production. 26 Replacing these rapid changes with gradual increases in mitochondrial ROS production and Ca 2+ accumulation would offer a better chance for the survival of mitochondria during reoxygenation. In the present study, we showed that post-hypoxic treatment with NecroX-5 provides a strong protection of rat heart mitochondria against reoxygenation injury by reducing mitochondrial oxidative stress, preserving DCm, improving mitochondrial oxygen consumption, and attenuating mitochondrial Ca 2+ accumulation. In addition, mitochondrial Ca 2+ overload induced by HR, ouabain, or histamine was eliminated with NecroX-5 treatment, suggesting that NecroX-5 may act as an inhibitor of MCU.
Post-hypoxic treatment with NecroX-5 protects cardiac mitochondria against reoxygenation damage
In the present study, the mitochondrial protective role of NecroX-5 was clearly demonstrated by the improvement in mitochondrial oxygen consumption, the preservation of DCm, and the reduction in mitochondrial oxidative stress and the Ca 2+ overload under the HR condition. IR significantly damages the electron transport chain (ETC), 3 and therefore impairs the mitochondrial coupling of the electron flow (from NADH to O 2 through the ETC) and the proton ejection from mitochondrial matrix, consequently leading to a lower electrochemical gradient, which is further used to synthesize ATP. Although no difference in state 4 of oxygen consumption was observed between the HR and NecroX-5 groups, significantly higher ADP-dependent oxygen consumption (state 3 respiration) and markedly improved DCm after prolonged reoxygenation could account for the tighter coupling between the mitochondrial respiratory chain and oxidative phosphorylation in the NecroX-5 group. In agreement with our results, ischaemic preconditioning protected state 3 respiration against IR damage.
27
The breakdown of DCm also contributes to the destabilization of action potential repolarization during IR, leading to arrhythmias. 28 In this study, the higher DCm in the NecroX-5-treated group compared with that in the HR group ( Figure 2E-G) was essential in avoiding reoxygenation-induced hyper-contracture, 29 a marker of irreversible damage, and to improve postischaemic recovery. Therefore, NecroX-5 preserved mitochondrial integrity and myocyte viability, consistent with smaller infarct size ( Figure 1A and B), which is highly associated with the preservation of cardiac performance in the NecroX-5 group after HR treatment (see Supplementary material online, Results and Table S2 ). Reoxygenation-induced mitochondrial oxidative stress was also attenuated in the NecroX-5-treated group (Figure 2A-D) . This finding was consistent with our previous study 18 and supports an antioxidant effect of NecroX-5. Mitochondria are thought to be both a source of ROS generation and a target of ROS-induced damage in HR. Ischaemia damages the ETC and increases the net production of ROS 3 from complex I to complex III, 30 which in turn results in further mitochondrial ROS generation. 5 Inhibiting ROS levels via ROS scavengers could suppress mitochondrial depolarization. 31 Previous studies have also shown that the release of mitochondrial ROS may be involved in the disruption of mitochondrial Ca 2+ homeostasis 32, 33 and that a reduction in mitochondrial ROS production and mitochondrial Ca 2+ concentration could prevent the opening of mPTPs. The influx of Ca 2+ into the mitochondria during reoxygenation was inhibited in the NecroX-5 group, which had a lower mitochondrial Ca 2+ content compared with the HR group ( Figure 2H-J) , especially during reoxygenation. Owing to the high mitochondrial Ca 2+ content in the HR group, the myocytes of the HR group began to hypercontract. In a previous study, mitochondrial depolarization and elevated mitochondrial Ca 2+ concentration were associated with reoxygenationinduced hyper-contraction. 29 Mitochondrial Ca 2+ uptake can either inhibit or stimulate ROS production, depending on the respiratory substrate and the effect of Ca 2+ on DCm, 33 which has been implicated in triggering mitochondrial DNA mutations and cell death. 34 In our study, post-hypoxic treatment with NecroX-5 not only limited mitochondrial ROS generation but also inhibited mitochondrial Ca 2+ accumulation, which may further prevent the opening of mPTPs, as suggested in previous studies. 6, 35 Moreover, maintaining the mitochondrial Ca 2+ homeostasis function could contribute to the antioxidant effect of NecroX-5.
NecroX-5 may act as a novel MCU inhibitor
An essential finding of our study was a novel effect of NecroX-5 as an MCU inhibitor under pathological Ca 2+ overload conditions. A Figure S3 ), which clearly demonstrated that NecroX-5 has the same target as RuR. The effect was not seen with NecroX-5 pre-treatment (see Supplementary material online, Figure S6) . Thus, the effect of NecroX-5 appears to be mediated by high Ca 2+ concentration in mitochondria.
Experiments using histamine to induce an elevation of mitochondrial Ca 2+ confirmed the effect of NecroX-5 on MCU ( Figure 4D-F 41, 42 In the present study, the administration of NecroX-5
did not affect L-type Ca 2+ current ( Figure 5 ), suggesting that cardiac contraction initiated by this channel would not be affected by NecroX-5. Therefore, we propose that NecroX-5 directly regulates mitochondrial Ca 2+ homeostasis via MCU and suppresses mitochondrial damage in a model of HR injury. Dysregulated calcium homeostasis is an important factor involved in generating an arrhythmia, which is a major cause of sudden cardiac death. Lowering mitochondrial Ca 2+ influx by inhibiting MCU is a promising approach to reduce arrhythmia followed by reperfusion or other pathological conditions. 42 In this context, the newly demonstrated effect of NecroX-5 on MCU will be a useful experimental tool and provide insight into the regulatory mechanism of MCU and its anti-arrhythmia role. However, the molecular mechanism underlying NecroX-5-induced inhibition of MCU and its effect on preventing arrhythmia should be addressed in future by studies more extensive in terms of the molecular reaction.
Although the precise mechanism of action for NecroX-5 is still unclear, our results demonstrated significant cardiac protection by NecroX-5 when administered during reoxygenation. Because heart attacks are usually unpredictable, the actions of this compound that take place during reperfusion could be a potent way to ameliorate post-hypoxic cardiac injury. First, NecroX-5 still worked well and showed a cytoprotective effect, whereas little or no cytoprotective effect was observed in cells treated with other agents. 18 Secondly, the synthesized NecroX-5 is chemically and functionally similar to NecroX-7, which was presented as the most efficacious and safe compound to prevent IR injury during liver surgery. 19 It was also tested and investigated as a new drug in a Phase 1 clinical trial with indications for MI. Finally, the current data further establish the dual protective role of NecroX-5 during reoxygenation by inhibiting both mitochondrial ROS generation and mitochondrial Ca 2+ accumulation as a strategy to limit HR damage. However, limitations of this study must be acknowledged. We were unable to conduct all experiments at temperatures that mimic the body due to inadequate equipment. Cell-based analyses were carried out at room temperature. However, other experiments such as cardiac function, infarct size, isolated myocytes, and Langendorff perfusion protocols were conducted at 378C. Collectively, NecroX-5 showed protective functions on treated samples under any temperature condition. Because we focused our research interest in the mitochondrial MCU and cardioprotective effect of NecroX-5, the effect of NecroX-5 on the activity of TCA cycle remained unclear. In the future study, investigation of the NecroX-5 effect in the NADH and FADH 2 production and various enzymatic activities in TCA cycle during HR injury will provide more insight of the cellular protective effect of NecroX-5 in the view of mitochondrial energetics.
In conclusion, our data demonstrate that the new agent NecroX-5 exerts a novel cardioprotective effect on rat heart mitochondria against HR damage by inhibiting MCU activity. NecroX-5 is a promising agent for the attenuation of myocardial damage resulting from reoxygenation injury.
